For the year ending 2025-12-31, KURA had -$75,363K decrease in cash & cash equivalents over the period. -$70,696K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenue | 67,482 |
| Total operating expenses | 371,113 |
| Interest and other income, net | 26,774 |
| Interest expense | 1,512 |
| Income tax expense | 297 |
| Net loss | -278,666 |
| Share-based compensation expense | 37,108 |
| Amortization of premium and accretion of discounts on short-term investments, net | 8,488 |
| Depreciation expense | 1,032 |
| Non-cash interest expense | 515 |
| Accounts receivable, net | 6,744 |
| Inventory | 413 |
| Prepaid expenses and other current assets | 15,950 |
| Accounts payable | 4,499 |
| Accrued expenses and other current liabilities | 12,654 |
| Operating lease right-of-use and other long-term assets | 6,363 |
| Other long-term liabilities | 1,043 |
| Contract liabilities | 195,715 |
| Net cash (used in) provided by operating activities | -64,058 |
| Purchases of short-term investments | 761,588 |
| Maturities of short-term investments | 755,128 |
| Purchases of property and equipment | 6,638 |
| Net cash (used in) provided by investing activities | -13,098 |
| Proceeds from issuance of stock under equity plans | 1,793 |
| Proceeds from issuances of common stock and pre-funded warrants, net of offering costs | 0 |
| Net cash provided by financing activities | 1,793 |
| Net (decrease) increase in cash and cash equivalents | -75,363 |
| Cash and cash equivalents at beginning of period | 224,462 |
| Cash and cash equivalents at end of period | 149,099 |
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)